Announcements Trials

Browse Landscape

Phase

Status

Terminated 1 Completed 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Metastatic Castration Resistant Prostate Cancer 1

Interventions

Cyclophosphamide 391 Carboplatin 344 Gemcitabine 332 pembrolizumab 331 Cisplatin 328 Paclitaxel 298 Radiotherapy 297 Docetaxel 287 Bevacizumab 253 Rituximab 234 Capecitabine 224 Nivolumab 222 Dexamethasone 206 Fluorouracil 190 fludarabine 178 Oxaliplatin 177 Pemetrexed 153 Doxorubicin 153 Irinotecan 148 Leucovorin 144 Etoposide 144 Cytarabine 134 Cetuximab 130 fludarabine phosphate 129 Bortezomib 129 Lenalidomide 126 Filgrastim 120 Erlotinib Hydrochloride 120 Temozolomide 113 Radiosurgery 113

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × tildrakizumab × Clear all

NCT04458311 2024-04-25

ACTIon

Institute of Cancer Research, United Kingdom

Phase 1/2 Terminated

Metastatic Castration Resistant Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡